AI Engines For more Details: Perplexity Kagi Labs You
Analgesic Effect: Clonixin lysinate is primarily used to relieve pain of mild to moderate intensity. It exerts its analgesic effects by inhibiting the synthesis of prostaglandins, which are substances involved in the mediation of pain and inflammation. By reducing prostaglandin levels, clonixin lysinate helps alleviate pain associated with conditions such as headache, dental pain, menstrual cramps, musculoskeletal injuries, and postoperative pain.
Anti-inflammatory Effect: Clonixin lysinate possesses anti-inflammatory properties, making it useful in the management of inflammatory conditions such as arthritis, bursitis, tendonitis, and other musculoskeletal disorders. By inhibiting the production of prostaglandins and other inflammatory mediators, clonixin lysinate helps reduce swelling, redness, and stiffness associated with inflammation, thereby improving symptoms and functional mobility.
Antipyretic Effect: In addition to its analgesic and anti-inflammatory effects, clonixin lysinate has antipyretic properties, meaning it can help reduce fever. By inhibiting the synthesis of prostaglandins in the brain's hypothalamus, clonixin lysinate helps lower body temperature and alleviate fever associated with infectious diseases, inflammatory conditions, or other causes.
Rheumatic Conditions: Clonixin lysinate may be prescribed for the management of rheumatic conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. It can help reduce pain, inflammation, and stiffness associated with these conditions, thereby improving joint function and quality of life for affected individuals.
Dosage and Administration: Clonixin lysinate is typically administered orally in the form of tablets or capsules, although intravenous formulations may also be available for certain medical settings. The dosage and frequency of clonixin lysinate therapy depend on factors such as the severity of pain or inflammation, the individual patient's response to treatment, and the specific formulation used. Patients should follow the instructions provided by their healthcare provider or medication label for proper dosing and administration.
Side Effects: Like other NSAIDs, clonixin lysinate may be associated with certain side effects, particularly when used at high doses or for prolonged periods. Common side effects may include gastrointestinal disturbances such as dyspepsia, nausea, vomiting, abdominal pain, and diarrhea. Less common but more serious side effects may include gastrointestinal ulcers or bleeding, cardiovascular events such as heart attack or stroke, renal impairment, allergic reactions, and liver toxicity. Patients should be monitored regularly for signs of adverse effects, especially if they have preexisting medical conditions or risk factors.
Contraindications and Precautions: Clonixin lysinate is contraindicated in individuals with hypersensitivity to NSAIDs or any of their components, as well as in patients with a history of aspirin-induced asthma, peptic ulcer disease, gastrointestinal bleeding, severe renal impairment, or hepatic dysfunction. It should be used with caution in elderly patients, individuals with cardiovascular risk factors, and those taking other medications that may interact with clonixin lysinate.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.4 | 0.3 | 10.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.3 | 1.6 | 1.06 |
| Allergies | 4.1 | 2.7 | 0.52 |
| Allergy to milk products | 1.8 | 1.6 | 0.13 |
| Alopecia (Hair Loss) | 0.9 | 0.9 | |
| Alzheimer's disease | 5.1 | 4.2 | 0.21 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.5 | 1 | 1.5 |
| Ankylosing spondylitis | 3.6 | 1.5 | 1.4 |
| Anorexia Nervosa | 1.5 | 2.4 | -0.6 |
| Antiphospholipid syndrome (APS) | 1.6 | 0.3 | 4.33 |
| Asthma | 4.7 | 1.5 | 2.13 |
| Atherosclerosis | 2.3 | 1.4 | 0.64 |
| Atrial fibrillation | 2.9 | 2.5 | 0.16 |
| Autism | 6.2 | 7.1 | -0.15 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.1 | 2.1 | |
| Bipolar Disorder | 2.1 | 1.1 | 0.91 |
| Brain Trauma | 0.6 | 1.4 | -1.33 |
| Breast Cancer | 1.2 | 1.2 | |
| Cancer (General) | 0.6 | 1.6 | -1.67 |
| Carcinoma | 4.1 | 2.2 | 0.86 |
| Celiac Disease | 2 | 2.7 | -0.35 |
| Cerebral Palsy | 1.1 | 1.1 | 0 |
| Chronic Fatigue Syndrome | 4.2 | 4.5 | -0.07 |
| Chronic Kidney Disease | 3 | 1.1 | 1.73 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.2 | 1.4 | 0.57 |
| Chronic Urticaria (Hives) | 1.8 | 1 | 0.8 |
| Coagulation / Micro clot triggering bacteria | 2 | 1.1 | 0.82 |
| Cognitive Function | 2.2 | 1.6 | 0.38 |
| Colorectal Cancer | 6 | 2.1 | 1.86 |
| Constipation | 1.2 | 0.6 | 1 |
| Coronary artery disease | 2.5 | 1.9 | 0.32 |
| COVID-19 | 6.5 | 8 | -0.23 |
| Crohn's Disease | 7.8 | 3.8 | 1.05 |
| Cushing's Syndrome (hypercortisolism) | 0.1 | 0.3 | -2 |
| cystic fibrosis | 1.3 | 1.2 | 0.08 |
| d-lactic acidosis (one form of brain fog) | 0.7 | 0.7 | |
| deep vein thrombosis | 2.5 | 1.4 | 0.79 |
| Denture Wearers Oral Shifts | 1.4 | 1.4 | |
| Depression | 7.9 | 5.3 | 0.49 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2 | 1.9 | 0.05 |
| Endometriosis | 3.4 | 2.1 | 0.62 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2.9 | 1.6 | 0.81 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 2.6 | 2.2 | 0.18 |
| Functional constipation / chronic idiopathic constipation | 4.3 | 3.9 | 0.1 |
| gallstone disease (gsd) | 3.9 | 1.1 | 2.55 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 0.3 | 3 |
| Generalized anxiety disorder | 3.1 | 1.6 | 0.94 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.5 | 0.5 | 2 |
| Graves' disease | 1.3 | 2.6 | -1 |
| Gulf War Syndrome | 0.8 | 1.3 | -0.63 |
| Halitosis | 1.3 | 0.3 | 3.33 |
| Hashimoto's thyroiditis | 2.7 | 0.9 | 2 |
| Heart Failure | 4.2 | 1.1 | 2.82 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 1.5 | 0.6 | 1.5 |
| hypercholesterolemia (High Cholesterol) | 1.2 | 1.2 | |
| hyperglycemia | 1.9 | 1 | 0.9 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.6 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 3.4 | 4 | -0.18 |
| Hypothyroidism | 0.6 | -0.6 | |
| Hypoxia | 3.1 | 0.3 | 9.33 |
| IgA nephropathy (IgAN) | 1.6 | 3.5 | -1.19 |
| Inflammatory Bowel Disease | 5.3 | 5.9 | -0.11 |
| Insomnia | 2 | 1.4 | 0.43 |
| Intelligence | 2.1 | 0.6 | 2.5 |
| Intracranial aneurysms | 1.3 | 0.3 | 3.33 |
| Irritable Bowel Syndrome | 6.4 | 3.2 | 1 |
| ischemic stroke | 2.5 | 1.4 | 0.79 |
| Liver Cirrhosis | 6.4 | 4 | 0.6 |
| Long COVID | 4.3 | 5.1 | -0.19 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.3 | 0.9 | 0.44 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.4 | 0.9 | 0.56 |
| ME/CFS with IBS | 0.5 | 1.4 | -1.8 |
| ME/CFS without IBS | 1.1 | 2 | -0.82 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.6 | 0.5 | 0.2 |
| Metabolic Syndrome | 7.1 | 5.8 | 0.22 |
| Mood Disorders | 6.6 | 4.6 | 0.43 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.9 | |
| Multiple Sclerosis | 4.1 | 4.6 | -0.12 |
| Multiple system atrophy (MSA) | 0.6 | -0.6 | |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 2.2 | -2.2 | |
| Neuropathy (all types) | 0.3 | 2.2 | -6.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.3 | 1.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.7 | 2.4 | 0.96 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | 0 |
| Obesity | 8.6 | 7 | 0.23 |
| obsessive-compulsive disorder | 3.9 | 3.3 | 0.18 |
| Osteoarthritis | 2.6 | 1.2 | 1.17 |
| Osteoporosis | 1.9 | 1.2 | 0.58 |
| pancreatic cancer | 1 | 0.3 | 2.33 |
| Parkinson's Disease | 5.8 | 4.7 | 0.23 |
| Polycystic ovary syndrome | 6 | 3.1 | 0.94 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.3 | 0.4 | -0.33 |
| primary biliary cholangitis | 0.9 | 1.4 | -0.56 |
| Primary sclerosing cholangitis | 1.5 | 2.1 | -0.4 |
| Psoriasis | 2.8 | 2.4 | 0.17 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7 | 3.2 | 1.19 |
| Rosacea | 0.6 | 0.7 | -0.17 |
| Schizophrenia | 4 | 2.3 | 0.74 |
| scoliosis | 1 | 0.6 | 0.67 |
| Sjögren syndrome | 2.2 | 2.3 | -0.05 |
| Sleep Apnea | 1.7 | 1.4 | 0.21 |
| Slow gastric motility / Gastroparesis | 1.3 | 0.3 | 3.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2 | 0.2 | 9 |
| Stress / posttraumatic stress disorder | 3.3 | 1.8 | 0.83 |
| Systemic Lupus Erythematosus | 4 | 1.4 | 1.86 |
| Tic Disorder | 0.9 | 1.5 | -0.67 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 2.7 | 2.7 | 0 |
| Type 2 Diabetes | 6.7 | 6.4 | 0.05 |
| Ulcerative colitis | 4.4 | 5.2 | -0.18 |
| Unhealthy Ageing | 3.6 | 1.9 | 0.89 |
| Vitiligo | 2 | 1.1 | 0.82 |
